Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
暂无分享,去创建一个
[1] Merlin C. Thomas,et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.
[2] Merlin C. Thomas,et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.
[3] S. Vatner,et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. , 2003, American journal of physiology. Heart and circulatory physiology.
[4] G. Jerums,et al. The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] Merlin C. Thomas,et al. A Breaker of Advanced Glycation End Products Attenuates Diabetes‐Induced Myocardial Structural Changes , 2003, Circulation research.
[6] A. Enomoto,et al. An inhibitor of advanced glycation end product formation reducesNϵ-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats , 2003 .
[7] A. Enomoto,et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] T. Kislinger,et al. RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.
[9] M. Cooper,et al. Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.
[10] S. S. Samra,et al. Accelerated atherosclerosis. , 2002, Journal of the Indian Medical Association.
[11] V. D’Agati,et al. Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[12] G. Romeo,et al. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. , 2000, Diabetes.
[13] D. Choudhury,et al. Advanced glycation end products: a Nephrologist's perspective. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] R. Nagaraj,et al. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. , 1999, Archives of biochemistry and biophysics.
[15] Alan W. Stitt,et al. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. , 1998, Investigative ophthalmology & visual science.
[16] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[17] M. Nangaku,et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. , 1998, Biochemical and biophysical research communications.
[18] G. Jerums,et al. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.
[19] A. Schmidt,et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[20] G. Jerums,et al. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.
[21] A. Cerami,et al. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. , 1988, Diabetes/metabolism reviews.
[22] A. Cerami,et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.
[23] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.